Cancer Research Technology Limited

Pritom Shah

Martin Stockley

Allan Michael Jordan

James R Hitchin

Niall M Hamilton

Irene Farre Gutierrez

Ellen Catherine MacDonald

Francesca Blum

James Lindsay Carr

Maria Del Mar Jimenez Quesada

Martin Lee Stockley

The present invention relates to compounds of formula I wherein A, A, A, R, R, R, R, R, R, L, Ar and Q are each as defined herein. The compounds of the present invention are inhibitors of autotaxin (ATX) enzyme activity. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions (e.g. fibrosis) in which ATX activity is implicated.

Autotaxin inhibitory compounds

The present invention relates to compounds of formula I, wherein A, A, A, R, R, R, R, R, R, L, Ar and Q are each as defined herein. The compounds of the present invention are inhibitors of autotaxin (ATX) enzyme activity. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions (e.g. fibrosis) in which ATX activity is implicated. 

The present invention relates to compounds of formula I wherein R, R, R, R, R, R, R, L, A, Q, W and HET are each as defined herein. The compounds of the present invention are inhibitors of autotaxin (ATX) enzyme activity. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions (e.g. fibrosis) in which ATX activity is implicated.

Autotaxin inhibitors

The present invention relates to compounds of formula (I): wherein R, R, R, R, R, R, R, L, A, Q, W and HET are each as defined herein. The compounds of the present invention are inhibitors of autotaxin (ATX) enzyme activity. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions (e.g. fibrosis) in which ATX activity is implicated. 

Growing community of inventors

Cambridge, United Kingdom

Pritom Shah